Irsenontrine
| Code | Size | Price |
|---|
| TAR-T38899-5mg | 5mg | £503.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Irsenontrine (E2027) is an orally active and selective phosphodiesterase 9 ( PDE9 ) inhibitor. Irsenontrine can be used for the research of neurological diseases.
CAS:
1429509-82-9
Formula:
0
Molecular Weight:
0
Purity:
0.98
SMILES:
0
References
Hershey LA, et al. Pharmacological Management of Dementia with Lewy Bodies. Drugs Aging. 2019;36(4):309-319.
Eisai to present latest research on Alzheimer?s disease / dementia pipeline at the 14th international conference on Alzheimer?s & Parkinson?s diseases
Miyamoto, et al. Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine. WO2018221550 A1